Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California


Purpose:

The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.


Criteria:

Inclusion Criteria: - Female with non child-bearing potential - Diagnosed Diabetes Mellitus patients treated with insulin alone or insulin in combination with other anti-diabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start. - HbA1c below or equal to 11 % at screening (HbA1c value according to international DCCT standard) Exclusion Criteria: - Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP - History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease - Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.


NCT ID:

NCT00768105


Primary Contact:

Study Director
Klas Malmberg, MD, PhD
AstraZeneca R&D Mölndal


Backup Contact:

N/A


Location Contact:

Chula Vista, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.